Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023

Back Bay Life Science Report

As we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including the December CRISPR and Vertex approval of Exa-cel, Biogen and Sage’s August approval of an oral treatment for women with postpartum depression and Genmab and Roche’s May approval in oncology.

In this episode:

• CRISPR and Vertex’s approval of Exa-cel, the first CRISPR-based genetic medicine approved by the FDA in the US
• The major depressive disorder vs. postpartum depression for Biogen/Sage
• GenMab and Roche approvals
• AbbVie acquisition of Cerevel Therapeutics strengthen neuroscience pipeline

In 2023, on The Life Science Report, Back Bay covered a wide range of topics featuring stories from the frontline of healthcare development to the rising trends in cardiology to the transactional landscape of antibody drug conjugates. We always welcome listener questions or topics you’d like to learn more about. You can listen to previous episodes or submit your inquiries here.

Back Bay provides a snapshot of the healthcare markets every Monday. For IPO, Follow-On and M&A updates, subscribe to our healthcare updates.